Atara Biotherapeutics’ allogeneic Tab-cel® platform allows for the manufacturing of a T-cell library in advance of patient’s need. Tab-cel® utilizes Epstein-Barr Virus (EBV) T‑Cells from donors with healthy immune function, which are then selected and expanded to recognize cancer cells. Thus, EBV T cells are naturally immune to Graft-versus-Host Disease (GvHD) without further need for gene editing, a common challenge in off-the-shelf cell therapy.
At Atara, we are bringing together core technologies and capabilities to develop next-generation off-the-shelf CAR-T immunotherapies, leveraging the unique features of the Tab-cel® platform. We are also collaborating with academic leaders and leveraging our world-class T-cell manufacturing and research expertise with the goal of rapidly advancing our CAR T programs.
The Director - CAR-T Platform Development Lead is an integral member of the Preclinical Research Laboratory Group and brings extensive engineered T cell product development expertise. This role oversees the development of the next generation of allogeneic, off-the-shelf CAR-T therapies for our expanding pipeline, with special interest to the challenges posed by the immunosuppressive nature of the tumor microenvironment. The candidate must have an established record of leadership in an industry setting with extensive laboratory-based CAR-T cell expertise.
Reports to Sr. Director of Preclinical & Translational Science
Location Thousand Oaks (northwest Los Angeles area), CA
Travel May be required (up to 10%).